Skip to main content

Abstract 159: Recurrent Ischemic Stroke And Cigarette Smoking: A Secondary Analysis Of The POINT Trial

Publication ,  Conference
Lang, A; Mac Grory, B; de Havenon, AH; Henninger, N; Furie, KL; Easton, JD; Kim, AS; Johnston, SC; Yaghi, S
Published in: Stroke
February 2022

Recent data suggest that in patients with acute myocardial infarction (MI), the effect of clopidogrel on risk reduction of cardiovascular outcomes is more pronounced in smokers. The aim of this study was to determine the effect of smoking status on subsequent stroke risk in patients with minor ischemic stroke or TIA and determine whether smoking improves the effect of clopidogrel treatment on subsequent stroke risk reduction. This was a post-hoc analysis of the Platelet Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trial. The POINT trial compared clopidogrel plus aspirin (DAPT) to aspirin alone for prevention of recurrent stroke, myocardial infarction, or vascular death within 3 months of a high-risk TIA or minor ischemic stroke. We used multivariable cox-regression models to determine the effect of smoking on the risk of subsequent ischemic stroke. We also performed interaction analyses to determine whether the effect of clopidogrel on subsequent ischemic stroke differed with respect to smoking status. Data from 4,877 participants enrolled in the POINT trial were analyzed. Among these, 1,004 were current smokers and 3,873 were non-smokers. Smoking was associated with a non-significantly increased risk of recurrent ischemic stroke during follow up (hazard ratio, 1.31 [95% CI, 0.97 - 1.78], P=0.076). The effect of clopidogrel on ischemic stroke was not significantly different in non-smokers (hazard ratio, 0.74 [95% CI, 0.56 - 0.98], P=0.03) compared to smokers (adjusted hazard ratio, 0.63 [95% CI, 0.37 - 1.05], P=0.078), P for interaction = 0.572. In addition, the effect of clopidogrel on major hemorrhage was not significantly different in current smokers (hazard ratio, 2.59 [95% CI, 1.08 - 6.21], P=0.032) compared to non-smokers (hazard ratio, 1.67 [95% CI, 0.40 - 7.00], P=0.481), P for interaction = 0.613. Cigarette smoking was associated with a non-significantly higher risk of subsequent ischemic stroke and smoking did not modify the effect of clopidogrel-based dual antiplatelet therapy on subsequent ischemic stroke risk reduction. Every effort should be made to encourage tobacco dependence treatment and cessation in patients with minor ischemic stroke and TIA.

Duke Scholars

Published In

Stroke

DOI

EISSN

1524-4628

ISSN

0039-2499

Publication Date

February 2022

Volume

53

Issue

Suppl_1

Publisher

Ovid Technologies (Wolters Kluwer Health)

Related Subject Headings

  • Neurology & Neurosurgery
  • 4201 Allied health and rehabilitation science
  • 3209 Neurosciences
  • 3202 Clinical sciences
  • 1109 Neurosciences
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lang, A., Mac Grory, B., de Havenon, A. H., Henninger, N., Furie, K. L., Easton, J. D., … Yaghi, S. (2022). Abstract 159: Recurrent Ischemic Stroke And Cigarette Smoking: A Secondary Analysis Of The POINT Trial. In Stroke (Vol. 53). Ovid Technologies (Wolters Kluwer Health). https://doi.org/10.1161/str.53.suppl_1.159
Lang, Adam, Brian Mac Grory, Adam H. de Havenon, Nils Henninger, Karen L. Furie, J. D. Easton, Anthony S. Kim, S. C. Johnston, and Shadi Yaghi. “Abstract 159: Recurrent Ischemic Stroke And Cigarette Smoking: A Secondary Analysis Of The POINT Trial.” In Stroke, Vol. 53. Ovid Technologies (Wolters Kluwer Health), 2022. https://doi.org/10.1161/str.53.suppl_1.159.
Lang A, Mac Grory B, de Havenon AH, Henninger N, Furie KL, Easton JD, et al. Abstract 159: Recurrent Ischemic Stroke And Cigarette Smoking: A Secondary Analysis Of The POINT Trial. In: Stroke. Ovid Technologies (Wolters Kluwer Health); 2022.
Lang, Adam, et al. “Abstract 159: Recurrent Ischemic Stroke And Cigarette Smoking: A Secondary Analysis Of The POINT Trial.” Stroke, vol. 53, no. Suppl_1, Ovid Technologies (Wolters Kluwer Health), 2022. Crossref, doi:10.1161/str.53.suppl_1.159.
Lang A, Mac Grory B, de Havenon AH, Henninger N, Furie KL, Easton JD, Kim AS, Johnston SC, Yaghi S. Abstract 159: Recurrent Ischemic Stroke And Cigarette Smoking: A Secondary Analysis Of The POINT Trial. Stroke. Ovid Technologies (Wolters Kluwer Health); 2022.

Published In

Stroke

DOI

EISSN

1524-4628

ISSN

0039-2499

Publication Date

February 2022

Volume

53

Issue

Suppl_1

Publisher

Ovid Technologies (Wolters Kluwer Health)

Related Subject Headings

  • Neurology & Neurosurgery
  • 4201 Allied health and rehabilitation science
  • 3209 Neurosciences
  • 3202 Clinical sciences
  • 1109 Neurosciences
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology